Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia

Results from the ESCALATOR study

Ali Taher, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler-Krahn, Bernard Roubert, Amal El-Beshlawy

Research output: Contribution to journal › Article

6 Citations (Scopus)

Abstract

This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P

Original languageEnglish
Pages (from-to)349-354
Number of pages6
JournalEuropean Journal of Haematology
Volume87
Issue number4
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Body Burden
Thalassemia
Iron
Liver
Therapeutics
Weights and Measures
deferasirox

Keywords

  • β-thalassaemia
  • Deferasirox
  • Efficacy
  • Iron chelation therapy
  • Iron overload

ASJC Scopus subject areas

  • Hematology

Cite this

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia : Results from the ESCALATOR study. / Taher, Ali; Elalfy, Mohsen S.; Al Zir, Kusai; Daar, Shahina; Al Jefri, Abdullah; Habr, Dany; Kriemler-Krahn, Ulrike; Roubert, Bernard; El-Beshlawy, Amal.

In: European Journal of Haematology, Vol. 87, No. 4, 10.2011, p. 349-354.

Research output: Contribution to journal › Article

Taher, A, Elalfy, MS, Al Zir, K, Daar, S, Al Jefri, A, Habr, D, Kriemler-Krahn, U, Roubert, B & El-Beshlawy, A 2011, 'Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study', European Journal of Haematology, vol. 87, no. 4, pp. 349-354. https://doi.org/10.1111/j.1600-0609.2011.01661.x
Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D et al. Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study. European Journal of Haematology. 2011 Oct;87(4):349-354. https://doi.org/10.1111/j.1600-0609.2011.01661.x
Taher, Ali ; Elalfy, Mohsen S. ; Al Zir, Kusai ; Daar, Shahina ; Al Jefri, Abdullah ; Habr, Dany ; Kriemler-Krahn, Ulrike ; Roubert, Bernard ; El-Beshlawy, Amal. / Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia : Results from the ESCALATOR study. In: European Journal of Haematology. 2011 ; Vol. 87, No. 4. pp. 349-354.
@article{8b02e0f0bd9a49acbcab074dc2e2868b,
title = "Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study",
abstract = "This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P",
keywords = "β-thalassaemia, Deferasirox, Efficacy, Iron chelation therapy, Iron overload",
author = "Ali Taher and Elalfy, {Mohsen S.} and {Al Zir}, Kusai and Shahina Daar and {Al Jefri}, Abdullah and Dany Habr and Ulrike Kriemler-Krahn and Bernard Roubert and Amal El-Beshlawy",
year = "2011",
month = "10",
doi = "10.1111/j.1600-0609.2011.01661.x",
language = "English",
volume = "87",
pages = "349--354",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia

T2 - Results from the ESCALATOR study

AU - Taher, Ali

AU - Elalfy, Mohsen S.

AU - Al Zir, Kusai

AU - Daar, Shahina

AU - Al Jefri, Abdullah

AU - Habr, Dany

AU - Kriemler-Krahn, Ulrike

AU - Roubert, Bernard

AU - El-Beshlawy, Amal

PY - 2011/10

Y1 - 2011/10

N2 - This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P

AB - This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P

KW - β-thalassaemia

KW - Deferasirox

KW - Efficacy

KW - Iron chelation therapy

KW - Iron overload

UR - http://www.scopus.com/inward/record.url?scp=80053284827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053284827&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2011.01661.x

DO - 10.1111/j.1600-0609.2011.01661.x

M3 - Article

VL - 87

SP - 349

EP - 354

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 4

ER -

Access to Document